|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma显示文摘INTRODUCTION Hepatocellular carcinoma(HCC)is the mostcommon cause of death from cancer in China.Themechanisms of hepatocarcinogenesis are not yetknown clearly,p16INK4a gene,the multiple tumorsuppressor gene 1(MTS1),encodes P16 protein,which acts as an inhibitor by binding directly toCDK4 and CDK6 and preventing its association | Yang Qin Bo Li Yong Shu Tan Zhi Lin Sun Feng Qiong Zuo Ze Fang Sun Institute of Biochemistry and Molecular Biology,West China University of Medical Sciences,Chengdu 610041,Sichuan Province,China Department of General Surgery,The First Affiliated Hospital,West China University of Medical Sciences,Chengdu 610041,Sichuan Province,China Department of Pathology,The First Affiliated Hospital,West China University of Medical Sciences,Chengdu 610041,Sichuan Province,China | 2000 | World Journal of Gastroenterology2000，6，3： | 30 |
| 2 | A new scoring system for assessment of liver function after successful hepatectomy in patients with hepatocellular carcinoma显示文摘BACKGROUND:Whether a major liver resection is safe has been judged mainly from the patient's hepatic reserve.However,a safe limit for liver resection does not exist yet.This study aimed to construct a new scoring system as a guide to determine a safe limit for liver resection and avoid liver dysfunction after hepatectomy.METHODS:Eighty-six patients with hepatocellular carcinoma who had undergone hepatectomy in West China Hospital from March 2007 to June 2010 were reviewed.The patients were classified according to the levels of total bilirubin after hepatectomy and the parameters in the perioperative period were compared.Receiver operating characteristic (ROC) analysis was made to assess the liver function compensatory (LFC) value to predict liver dysfunction of the patients after hepatectomy.LFC value is defined as the preoperative KICG value×22.487+standard remnant liver volume (SRLV)×0.020.RESULTS:Patients were classified into group Ⅰ (normal group,n=69) and group Ⅱ (with total bilirubin >85.5 μmol/L for 7 days after hepatectomy,n=17) based on the levels of total bilirubin after hepatectomy.Group II was further divided into two subgroups:recovered subgroup (n=14) and fatal subgroup (n=3).There were no significant differences in preoperative data or intraoperative findings except the indocyanine green test parameters (KICG and ICG R15) and SRLV.ROC analysis showed that the sensitivity and specificity of an LFC value ≤13.01 were 94.1% and 82.6% respectively for predicting liver dysfunction of the patients after hepatectomy.CONCLUSIONS:The LFC value appears to be a good predictor of postoperative liver dysfunction in patients who undergo hepatectomy for HCC.An expected LFC value of 13.01 seems to be a safe limit for liver resection. | Zheng-Gui Du,Bo Li,Yong-Gang Wei,Jie Yin,Xi Feng and Xi Chen Department of Liver and Vascular Surgery,West China Hospital,Sichuan University,Chengdu 610041,China | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，3： | 23 |
| 3 | Liver transplantation for patients with hepatolithiasis显示文摘Because of its complicated pathological features such as repeated cholangitis and multiple operations, hepatolithiasis is difficult to treat and often lead to portal hypertension, and liver failure. The aim of this study was to investigate the indications of orthotopic liver transplantation ( OLT) for patients with hepatolithiasis and the improvement of operative techniques and the treatment of postoperative complications. METHODS:The data of 4 patients with hepatolithiasis who had undergone OLT at our department in recent years were reviewed retrospectively. RESULTS:The 4 patients with hepatolithiasis complicated with secondary biliary cirrhosis in end-stage liver disease included 1 woman and 3 men. One patient underwent OLT using veno-venous bypass prior to the mobilization of the liver. Two patients were subjected to liver transplantation with improved piggyback technique without bypass. One patient received OLT without bypass. All patients were operated on successfully and recovered uneventfully. Patient 1 had bleeding from the digestive tract on the postoperative day 6. Patient 2 had hemorrhage from the digestive tract and a leakage of end-to-side intestinal anastomosis on the postoperative day 44. Patient 4 was reoperated on because of hemorrhage from the anastomotic stoma of the hepatic artery on the postoperative days 8 and 10. In the 4 patients the mean operative time was 7.9 hours and blood loss was 910 ml. Postoperative pathological analysis revealed biliary liver cirrhosis. Follow-up of all patients showed good conditions. CONCLUSIONS:Hepatolithiasis with secondary biliary liver cirrhosis in patients with end-stage liver disease is indicated for liver transplantation. Veno-venous bypass prior to the mobilization of the liver and improved piggyback tech- nique can lower the incidence of intraoperative bleeding, the duration of surgery and postoperative complications. | Guang-Dong Pan, Lu-Nan Yan, Bo Li, Shi-Chun Lu, Yong Zeng, Tian-Fu Wen, Ji-Chun Zhao, Nan-Sheng Cheng, Yu-Kui Ma, Wen-Tao Wang, Jia-Yin Yang and Zhi-Hui Li Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041 , China | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，3： | 13 |
| 4 | Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells显示文摘BACKGROUND: Multidrug resistance is a major obstacle in cancer chemotherapy. We examined whether the antisense RNA of multidrug resistance gene 1 (mdr1) could reverse multidrug resistance in the human hepatocellular carcinoma (HCC) cell line SMMC7721/ADM. METHODS: The recombinant adenoviruses pAdEasy- GFP-ASmdr1 product was produced by the adenoviral vector AdEasy system, which can express antisense RNA against the mdr1 gene. Following that, the recombinant adenovirus was transfected into the P-glycoprotein- producing multidrug resistance cell line, SMMC7721/ADM human HCC cells resistant to adriamycin (ADM) and daunorubicin (DNR). In order to investigate the reversal of multidrug resistance phenotype, we measured the expression of mdr1 mRNA by RT-PCR and the production of P-glycoprotein by flow cytometry. The sensitivities for ADM and DNR SMMC7721/ADM cells were examined by [3-(4, 5-dimethylthi-azol-2-yl)-2,5 diphenyl-terazolium bromide] (MTT) analysis. RESULTS: The low-level expression of mdr1 mRNA and P-glycoprotein production were observed in parental sensitive cells SMMC/7721 in addition to the overexpressionof mdr1 mRNA and P-glycoprotein in SMMC7721/ADM cells. The transfection of antisense-RNA into SMMC7721/ ADM cells resulted in decreases of mdr1 mRNA and P-glycoprotein, but increase of drug sensitivities. The sensitivities of transfected SMMC7721/ADM cells to ADM and DNR in IC50 reduced by 31.25% and 62.96% respectively. CONCLUSIONS: Mdr1 antisense RNA can increase the sensitivities of SMMC7721/ADM cells to anticancer drug by decreasing the expression of the mdr1 gene and inhibiting P-glycoprotein expression. This strategy may be applicable to cancer patients with P-glycoportein mediated multidrug resistance. | Bo Li, Tian Ye, Lei Zhao, De-Hua Li, Xing-Hua Gou, Lan-Ying Zhao, Lei Han, Lin Chen, Lu-Nan Yan and Jian-Ping Gong Department of Hepatobiliary Surgery, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China Department of Traditional Chinese Surgery, Second Affiliated Hospital, Luzhou Medical College, Luzhou 646000, China Genetic Engineering Laboratory, Chengdu Di’ao Group Co., Ltd., Chengdu 610041, China Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，4： | 10 |
| 5 | Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation显示文摘BACKGROUND: Combined hepatitis B immune globulin (HBIg) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients. This study was undertaken to evaluate the outcomes of liver transplantation for patients with hepatitis B virus (HBV). METHODS: A retrospective chart analysis and a review of the organ transplant database identified 51 patients (43 men and 8 women) transplanted for benign HBV-related cirrhotic diseases between June 2002 and December 2004 who had survived more than 3 months. HBIg was administered intravenously during the first week and intramuscularly thereafter. RESULTS: At a median follow-up of 14.1 months, the overall recurrence rate in the 51 patients was 3.9% (2/51). The overall patient survival was 88.3%, and 82.4% after 1 and 2 years, respectively. A daily oral dose of 100 mg lamivudine for 2 weeks before transplantation for 10 patients enabled 57.1% (4/7) and 62.5% (5/8) of HBV-DNA and HBeAg positive patients respectively to convert to be negative. Intramuscular HBIg was well tolerated in all patients. CONCLUSION: Lamivudine combined with intramuscular HBIg can effectively prevent allograft from the recurrence of HBV after liver transplantation. | Mao-Lin Yan, Lu-Nan Yan, Bo Li, Yong Zeng, Tian-Fu Wen, Wen-Tao Wang, Jia-Yin Yang, Ming-Qing Xu, Zhi-Hui Li and Yong-Bing Chen Liver Transplantation Group of Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，3： | 10 |
| 6 | Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation显示文摘BACKGROUND: Liver allograft hepatitis B virus (HBV) reinfection and hepatitis B (HB) recurrence jeopardize the long-term survival of recipient and liver allograft. Lamivu- dine has been referred as a novel antiviral agent against HBV in HBV cirrhotic patients even in liver transplantation setting. We assessed the prophylatic effect of lamivudine on liver allograft HBV reinfection and clarified the dynamic changes of HBV markers in HBV related decompensated liver cirrhosis after liver transplantation. METHODS: Twenty-five recipients were divided into three groups: HBV active replication group (15 recipients), HBV inactive replication group (7), and control group (3). 100 mg/d lamivudine was administered preoperatively except in the control group. The HBV markers of serial sera and liver biopsy samples of the 25 recipients were evaluated re- gularly with enzyme-linked radioimmunoassay, HBV DNA fluorecent quantitative assay, immunohistochemical stain- ing , labelled streptavidin biotin ( LSAB) and digoxin la- belled HBV DNA hybridization in situ. The dynamic alter- nation of HBV markers under lamivudine prophylaxis was observed. RESULTS: In the HBV active replication group who had received lamivudine 2 weeks before liver transplantation, serum HBV DNA positive converted to negative by 80%. HBsAg of all recipients disappeared after liver transplanta- tion , but corresponding antibodies of HBV appeared within one week after the operation. HBsAb 9/15, HBcAb 13/15 and HBeAb 11/15 appeared and subsided gradually within 24 weeks. HBV DNA in sera was kept negative; HBsAg, HBcAg and HBV DNA hybridization in situ of liver biopsy samples remained negative after use of lamivudine. Ten of the 15 recipients showed clearance of HBV, and per se HBV markers were undetectable both in serum and liver bi- opsy samples between 12 to 44 weeks (24 weeks on ave- rage). The 1-, 2-year survival rates were 83% in this group. Two of the 15 recipients developed HBV allograft reinfection or recurrence of hepatitis 2 years after lamivudi- ne monoprophylaxis (2/15, 13.3%). In the HBV inactive replication group, the outcome was similar to that of the HBV active group. The HBV antibody frequency was HBs- Ab 4/7, HBcAb 6/7, and HBeAb 2/7. Three of 7 recipients showed HBV clearance both in sera and liver biopsy sam- ples , whereas in the control group all 3 recipients developed HBV allograft reinfection and recurrent hepatitis 8, 10, 12 months postoperatively; one of them died of fibrosing cho- lestatic hepatitis, and the remaining 2 recovered after addi- tional lamivudine therapy. The overall allograft reinfection rate was 9.1% (2/22) and the overall 1-, 2-year survival rates were 87%) in the lamivudine prophylaxis group. CONCLUSIONS: Lamivudine prophylaxis can prevent ef- fectively liver allograft from HBV reinfection in patients with HBV-related decompensated liver cirrhosis even in HBV active replication recipient after liver transplantation. Its long-term outcome remains to be studied. | Shi-Chun Lu, Lu-Nan Yan, Bo Li, Tian-Fu Wen, Ji-Chun Zhao, Nan-Sheng Cheng, Chong Liu, Jun Liu, Xiao-Bo Wang, Xiao-Dong Li, Shan Qin, Lian-Shan Zhao, Bin-Jun Lei and Xiu-Hui Zhang Chengdu, China Department of Surgery Viral Hepa- titis Research Center Department of Pathology , West China Hospital, Sichuan University, Cheng- du 610041 , China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，1： | 9 |
| 7 | Modified techniques for adult-to-adult living donor liver transplantation显示文摘BACKGROUND: Because of critical organ shortage, transplant professionals have utilized living donor liver transplantation (LDLT) in recent years. We summarized our experience in adult-to-adult LDLT with grafts of right liver lobe by a modified technique. METHODS: From January 2002 to August 2005, 24 adult patients underwent living donor liver transplantation with grafts of the right liver lobe at West China Hospital, Sichuan University, China. Twenty-two patients underwent modi-Bed procedures designed to improve the reconstruction of the right hepatic vein and the tributaries of the middle hepatic vein by interposing a great saphenous vein ( GSV) graft and the anastomosis of the hepatic arteries and bile ducts. RESULTS: No severe complications and death occurred in all donors. In the first 2 patients, (patients 1 and 2), operative procedure was not modified. One patient suffered from 'small-for-size syndrome' and the other died of sepsis with progressive deterioration of graft function. In the rest 22 patients (patients 3 to 24), however, the procedure of venous reconstruction was modified, and better results were obtained. Complications occurred in 7 recipients including acute rejection (2 patients), hepatic artery thrombosis (1), bile leakage (1), intestinal bleeding (1), left sub-phrenic abscess (1), and pulmonary infection (1). One patient with pulmonary infection died of multiple organ failure (MOF). The 22 patients underwent direct anastomosis of the right hepatic vein to the inferior vena cava (IVC), 9 direct anastomosis plus the reconstruction of the right inferior hepatic vein, and 10 direct anastomosis plus the reconstruction of the tributaries of the middle hepatic vein by in-terpos-ing a GSV graft to provide sufficient venous outflow. Trifurcation of the portal vein was met in 3 patients. Venoplasty or separate anastomosis was performed. The ratio of graft to recipient body weight ranged from 0.72% to 1.17%. Among these patients, 19 had the ratio <1.0% and 4 <0.8%, and the ratio of graft weight to recipient standard liver volume was between 31.86% and 62.48%. Among these patients, 10 had the ratio <50% and 2 <40%. No 'small-for-size syndrome' occurred in the 22 recipients who were subjected to modified procedures. CONCLUSIONS: With the modified surgical techniques for the reconstruction of the hepatic vein to obtain an adequate outflow and provide a sufficient functioning liver mass, living donor liver graft in adults using the right lobe can be safe to prevent the 'small-for-size syndrome'. | Lu-Nan Yan, Bo Li, Yong Zeng, Tian-Fu Wen, Ji-Chun Zhao, Wen-Tao Wang, Jia-Yin Yang, Ming-Qing Xu,Yu-Kui Ma, Zhe-Yu Chen, Jiang-Wen Liu and Hong Wu Liver Transplantation Division, Department of Surgery, West China Hospital, Sichuan University, Chengdu 610041 , China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，2： | 6 |
| 8 | Construction of the recombinant adenovirus vector carrying antisense multidrug resistance gene显示文摘BACKGROUND: Multidrug resistance proteins serve as transporters for chemical drugs in human malignancies. The objective of this study was to construct a homologous recombinant adenovirus carrying a reversal fragment of multidrug resistance gene 1 (mdr1) gene cDNA sequence. METHODS: The fragment of the mdr1 gene from the plasmid pHaMDRI-1 carrying the whole human mdr1 cDNA sequence was inserted reversely into the shuttle plasmid pAdTrack-CMV of adenoviral vector system AdEasy. The homologous recombination process was taken place in E. coli BJ5183 with the backbone plasmid pAdEasy-1. After packaging in 293 cells, recombinant adenoviral plasmid was generated. The recombinant adenoviral plasmid was identified by polymerase chain reaction (PCR), restriction endonucleases digest, DNA sequence analysis and fluorescence microscopic photograph, respectively. RESULTS: The recombinant adenovirus pAdEasy-GFPASmdr1 was successfully constructed and identified by PCR, restriction digest, and sequencing with strong green fluorescence expression in fluorescence microscopic photograph. CONCLUSIONS: The recombinant adenoviral mdr1 vector would introduce the antisense mdr1 gene into the human multidrug resistance hepatocellular cell fine effectively, which would provide an experimental basis to study the multidrug resistance in human hepatocellular carcinoma. | Bo Li, Xing-Hua Gou, Lin Chen, De-Hua Li, Yong-Heng Zhao, Lei Han, Lan-Ying Zhao and Jian-ping Gong Department of Hepatobiliary Surgery, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China Genetic Engineering Laboratory, Chengdu Diao Group Co. Ltd., Chengdu 610041, China and Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China | 2006 | Hepatobiliary & Pancreatic Diseases International2006，5，1： | 6 |
| 9 | Analysis of CD8^+CD28^-T-suppressor cells in living donor liver transplant recipients显示文摘BACKGROUND:Human CD8 + CD28 - T-suppressor(Ts) cells have been considered to indicate a reduced need for immunosuppression in pediatric liver-intestine transplant recipients and recipients of deceased heart-kidney transplants.However,in adult-to-adult living donor liver transplantation(A-A LDLT)little information is available and the clinical significance is still unknown. METHODS:Flow cytometry was used to detect the population of CD8+CD28 -Ts cells present in peripheral blood in A-A LDLT recipients(n=31),patients with end- stage liver disease(n=24)and healthy controls(n=19). Meanwhile,we tested the graft function and trough levels of immunosuppression in recipients.The clinical and follow- up data of 31 transplant recipients were analyzed. RESULTS:Compared with diseased controls(P=0.007) and healthy individuals(P=0.000),a notable expansion of CD8 + CD28 - Ts cells was found in recipients of A-A LDLT.This was associated with graft function,levels of immunosuppression and rejection episodes. CONCLUSIONS:To monitor the CD8 + CD28 - Ts cells levels is important to evaluate the immune state of recipients. Meanwhile,it is also important to promote expansion of CD8+CD28 -Ts cells in recipients of A-A LDLT,not only to sustain good graft function and decrease the dosage of immunosuppressants,but also to reduce the occurrence of rejection. | Yi-Xin Lin,Lan-Lan Wang,Lu-Nan Yan,Pei Cai,Bo Li,Tian-Fu Wen and Yong Zeng Center of Liver Transplantation and Department of Surgery,Division of Clinical Immunology and Department of Laboratory Medicine,West China Hospital,Sichuan University,Chengdu610041,China | 2009 | Hepatobiliary & Pancreatic Diseases International2009，8，3： | 6 |
| 10 | Posttraumatic stress disorder after liver transplantation显示文摘BACKGROUND: Liver transplantation can lead to the development of posttraumatic stress disorder (PTSD), but the risk factors associated with this progression are not well understood. To study this syndrome in adult liver transplant recipients, a cross-sectional investigation of 296 recipients at our hospital was carried out between January and June 2010. METHODS: Study participants completed two questionnaires [a PTSD self-rating scale (PTSD-SS) and a validated Chinese version of the Medical Outcomes Study Short Form-36 (SF-36)]. Clinical and demographic data were collected from the records of the Chinese Liver Transplant Registry and via questionnaires. RESULTS: The prevalence of full PTSD and partial PTSD (that met the criteria for 2 of the 3 symptom clusters) was 3.7% and 5.4%, respectively, for all transplant recipients. Significant differences between the recipients with no PTSD, partial PTSD, and full PTSD were found in all SF-36 domains except for physical functioning (P=0.466). In general, domain scores were the highest in the recipients who did not meet the criteria for PTSD and the lowest in the recipients who met the criteria for full PTSD. Greater severity of posttraumatic stress symptoms was correlated with poorer quality of life, especially in the bodily pain (P=0.004), social functioning (P=0.001), role-emotional (P=0.048), and mental health (P<0.001) domains. The model for end-stage liver disease (MELD) scores, complications, and educational status were identified by multiple regression analysis as risk factors for developing PTSD. CONCLUSIONS: PTSD occurred after liver transplantation and was significantly associated with decreased quality of life. Higher MELD scores and complications after transplantation were risk factors that contributed to PTSD, and higher education was a protective factor. | Shu-Guang Jin, Lu-Nan Yan, Bo Xiang, Bo Li, Tian-Fu Wen, Ji-Chun Zhao, Ming-Qing Xu and Jia-Ying Yang Department of Pediatric Surgery and Department of Liver and Vascular Surgery , West China Hospital, Sichuan University, Chengdu 610041, China | 2012 | Hepatobiliary & Pancreatic Diseases International2012，11，1： | 5 |
| 11 | Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility:A meta-analysis显示文摘AIM: To assess the association between Interleu-kin-10 (IL-10) gene IL-10-1082 (G/A), IL-10-592(C/A), IL-10-819 (T/C) polymorphisms and hepatocellular carcinoma (HCC) susceptibility.METHODS: Two investigators independently searched the Medline, Embase, China National Knowledge Infrastructure, and Chinese Biomedicine Database. Summary odds ratios (ORs) and 95% conf idence intervals (95% CIs) for IL-10 polymorphisms and HCC were cal-culated in a fixed-effects model (the Mantel-Haenszel method) and a random-effects model (the DerSimonian and Laird method) when appropriate. RESULTS: This meta analysis included seven eligiblestudies, which included 1012 HCC cases and 2308 controls. Overall, IL-10-1082 G/A polymorphism was not associated with the risk of HCC (AA vs AG + GG, OR = 1.11, 95% CI = 0.90-1.37). When stratifying for ethnicity, the results were similar (Asian, OR = 1.12, 95% CI = 0.87-1.44; non-Asian, OR = 1.10, 95% CI = 0.75-1.60). In the overall analysis, the IL-10 polymorphism at position -592 (C/A) was identified as a genetic risk factor for HCC among Asians; patients carrying the IL-10-592*C allele had an increased risk of HCC (OR = 1.29, 95% CI = 1.12-1.49). No association was observed between the IL-10-819 T/C polymorphism and HCC susceptibility (TT vs TC + CC, OR = 1.02, 95% CI = 0.79-1.32).CONCLUSION: This meta-analysis suggests that IL-10-592 A/C polymorphism may be associated with HCC among Asians. IL-10-1082 G/A and IL-10-819 T/C polymorphisms were not detected to be related to the risk for HCC. | Yong-Gang Wei, Fei Liu, Bo Li, Xi Chen, Yu Ma, Lv-Nan Yan, Tian-Fu Wen, Ming-Qing Xu, Wen-Tao Wang, Jia-Yin YangYong-Gang Wei, Fei Liu, Bo Li, Xi Chen, Yu Ma, Lv-Nan Yan, Tian-Fu Wen, Ming-Qing Xu, Wen-Tao Wang, Jia-Yin Yang, Department of Liver and Vascular Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Prov- ince, China Author contributions: Wei YG and Liu F designed the study, collected and analyzed the data and wrote the manuscript Li B collected and analyzed the data and wrote the manuscript Chen X and Ma Y collected and analyzed the data Yan LN analyzed the data and contributed to the discussion Wen TF and Xu MQ revised the manuscript Wang WT and Yang JY contributed to the discussion Wei YG and Liu F contributed equally to this work. | 2011 | World Journal of Gastroenterology2011，17，34： | 3 |
| 12 | Predictors of patient survival following living donor liver transplantation显示文摘BACKGROUND: Living donor liver transplantation (LDLT) is considered to be the alterative choice in light of the great shortage of cadaveric donors. However, the characteristics of the patients who will benefit from LDLT have not been well identified. The aim of this study was to define the pre- and intra-operative factors that may influence patient outcome. METHODS: The data from 102 LDLT patients who had operations between 2002 and 2009 were collected and analyzed retrospectively. Data were analyzed using uni- and multi-variate analysis according to factors that are known to be associated with outcome in these patients. RESULTS: Overall, the accurate survival rate of recipients at 1, 3, and 5 years was 84%, 76%, and 70%, respectively. The independent risk factors, preoperative renal dysfunction, intraoperative red blood cell transfusions of greater than 5 units, and female to male match (donor to recipient matching), were identified by Cox regression analysis. The pre-transplant model for end-stage liver disease score and a graft to recipient weight ratio of less than 0.8% were not predictive of outcome. The overall 1-, 3-, and 5-year survival of patients with one or no risk factors and two or more risk factors were 91%, 86%, and 83% and 67%, 56%, and 47%, respectively (P<0.0001). CONCLUSIONS: In our retrospective study, preoperative renal dysfunction, intraoperative red blood cell transfusions of greater than 5 units, and female to male gender match were independent risk factors for LDLT recipient outcome. Two or more of these risk factors may contribute to poor outcome. | Chuan Li, Tian-Fu Wen, Lu-Nan Yan, Bo Li, Jia-Ying Yang, Wen-Tao Wang, Ming-Qing Xu and Yong-Gang Wei Division of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, China | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，3： | 3 |
| 13 | Single-dose daclizumab induction therapy in patients with liver transplantation显示文摘AIM: To investigate the efficacy and safety of a singledose daclizumab induction therapy in orthotopic liver transplantation (OLTx).METHODS: A retrospective study was made for 54 cases of OLTx in recent three years. The daclizumab group consisted of 23 cases of OLTx who received single-dose of 2 mg/kg intravenously after postoperative 24 hours. The control group consisted of the remaining 31 patients. Additional immunosuppressors included steroids, mycomphenolate mofetil, facrolimus or microemulsion cyclosporine used in all patients. Meta-statistical analysis was made for general data,incidence of acute rejection and infection, postoperative clinical course, complications and prognosis between two groups.RESULTS: Pretransplant demographies were not significantly different between two groups. In the induction group there were significantly less acute rejection episodes (5 of 23, 21.74 %) than those in the control group (12 of 31, 38.71%), which were proved by pathologic diagnosis (P<0.05). The incidence of infection at the early stage was not significantly different between two groups.CONCLUSION: Induction therapy with single-dose of daclizumab is safe and effective and appears to be able to reduce the incidence of acute rejection. | Lu-Nan Yan Wei Wang Bo Li Shi-Chun Lu Tian-Fu Wen Qi-Yuan Lin Yong Zeng Nan-Sheng Cheng Ji-Chun Zhao Yue-Meng Dai, Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China | 2003 | World Journal of Gastroenterology2003，9，8： | 2 |
| 14 | Venovenous bypass ahead of mobilization of the liver in orthotopic liver transplantation显示文摘BACKGROUND: To evaluate feasibility and safety of venovenous bypass prior to mobilization of the liverduring orthotopic liver transplantation (OLT).METHODS: Fifty-four patients were classified into two groups. Group A consisted of 23 patientsreceiving OLT with classical venovenous bypass. Group B consisted of 31 patients who received amodified-procedure: venovenous bypass ahead of the mobilization of the liver during ULT. The blood loss,duration of venovenous bypass, cold ischemia time, anhepatic phase, and transfusion during operation inthe two groups were compared. Complications after the operation were also compared between the twogroups.RESULTS: The duration of venovenous bypass and cold ischemia time in group A were longer than thosein group B [(99.78±21.36 min) vs (96.32±22.25 min) and (484.78±134.01 min) vs (443.15±85.27 min)]. The anhepatic phase lasted for about 100 min averagely in the two groups. The volumes ofblood loss and transfusion during the operation were larger in group A than in group B [(5096±4243 ml)vs (1726±1125 ml) and (3676±2938.74 ml) vs (1217.69±829.72 ml)]. Postoperative complicationsoccurred in 26 patients of group A and in 19 patients of group B.CONCLUSION: This modified-procedure or venovenous bypass ahead of mobilization of the liver in OLTcan reduce the blood loss during OLT and the incidence of postoperative complications withoutprolongation of the anhepatic phase and duration of venovenous bypass. | Lu-Nan Yan Wei Wang Bo Li Shi-Chun Lu Tian-Fu Wen Yong Zeng Nan-Sheng Cheng Ji-Chun Zhao Qi-Yuan Lin Xiao-Li Chen Xiao-Ding Wu Qian-Bin Jia Yong Zhou Bin Tu Yan-Tao Wu the Center of Liver Transplantation, West China Hospital, Sichuan University, Chengdu 610041, China | 2003 | Hepatobiliary & Pancreatic Diseases International2003，2，1： | 2 |
| 15 | Liver transplantation in patients with intrahepatic stones: report of two cases显示文摘To investigate the feasibility and rationality ofliver transplantation as an indication for patientswith intrahepatic stones.Methods: Liver transplantation was successfully per-formed for a 28-year-old man and a 42-year-oldwoman, both with intrahepatic stones.Results: Patient 1 had digestive tract bleeding on thepostoperative day 6 and he was discharged from thehospital on the postoperative day 25. He is in goodhealth 14 months after operation. Patient 2 also hadhemorrhage from the digestive tract on the postope-rative day 44 and a leakage of end-to-side intestinalanastomosis on the postoperative day 47. She has re-sumed her work and is in good health from the post-operative month 12.Conclusion: Liver transplantation is safe and effec-tive for patients with intrahepatic stones. | Lu-Nan Yan Shi-Chun Lu Bo Li Qi-Yuan Lin Tian-Fu Wen Yong Zeng, Nan-Sheng Cheng Ji-Chun Zhao Yong Zhou Bo-Le Tian Wei-Ming Hu Ye Shu the Department of Surgery, West China Hospital, Sichuan University, Chengdu 610041, China | 2002 | Hepatobiliary & Pancreatic Diseases International2002，1，3： | 2 |
| 16 | Silencing of the major salt- dependent isoform of pectinesterase in tomato alters fruit softening 显示文摘 | Phan T D Bo W West G | 2007 | Plant Physiology2007，144，4： | 1 |
| 17 | Evaluation outcomes of donors in living dono liver transplantation: a single-center analysis of 132 donors显示文摘BACKGROUND: Donor safety has always been a major concern and potential risk to the donor must be balanced against recipient benefit. However, lack of a standardized and uniform evaluation of perioperative complications is a serious limitation of the evaluation of donor morbidity. This study was designed to evaluate the outcomes of donors in adult living donor liver transplantation (LDLT) using the newer Clavien classification system in a single center in China. METHODS: We prospectively analyzed the outcomes of 132 consecutive living liver donors from 2005 to 2008 using the newer Clavien classification system. The preoperative, intraoperative and postoperative data of the donors were collected and analyzed Ordinal regression was used to analyze the ordered grades of complications. RESULTS: Ninety-four (71.2%) of the donors developed postoperative complications of grade I (n=45, 34.1%), grade II (n=39, 29.5%) and grade III (n=10, 7.6%). There was no death or grade IV morbidity. Hepatic functional impairment and pleural effusion were the most frequent morbidities for living donors. Fifty-three donors (40.1%) developed hepatic functional impairment of grade I (n=40, 31.1%) and grade II (n=13, 10.0%). The ICU stay (7.8±1.8 days) and length of hospital stay (17.7±4.6 days) were significantly longer in donors with grade III than others. Furthermore, ordinal logistic regression revealed that donor's older age (>40 years) and right hepatectomy were associated with morbidity. In addition, only preoperative total bilirubin (within the normal range) and postoperative nadir serum phosphorus were independently associated with hepatic functional impairment. The receiveroperator characteristic curve revealed that preoperative total bilirubin >18.0 μmol/L and postoperative nadir of serum phosphorus <1 mg/dL may lead to more severe hepatic functional impairment. CONCLUSIONS: Despite the fact that donors are relatively safe to undergo hepatectomy, many living donors still experience postoperative morbidity. Meticulous technical and preoperative donor evaluation and treatment are sure to reduce the incidence of complications. | Ding Yuan, Yong-Gang Wei, Bo Li, Lu-Nan Yan, Tian-Fu Wen, Ji-Chun Zhao, Yong Zeng and Ke-Fei Chen Department of Liver and Vascular Surgery, Liver Transplantation Center Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, China | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，5： | 1 |
| 18 | Oxidation of the Norditerpenoid Alkaloids Isotalatisidine and 6-Epiforsticine显示文摘Oxidation of 1 with KMnO4 in acetone-H2O (1:1) for 1h gave nevadenine 2 (38%). But. 3 was formed in 98% yield when prolonging time and raising temperature (40℃). Reaction of 1 and 10 with Conforth reagent afforded the ketones 11 (55%), 12 (30%), and 13 (13%), 14 (20%). respectively. While oxidation of 7 and 15 with a variety of the oxidizing agents gave 17 only in low 20% of yield besides the minor 16. In addition. 1 was converted to 2 by the fungi Curvularia lunata. | Zheng Bang LI Qiao Hong CHEN Feng Peng WANG Bo Gang LI (Department of Chemistry of Medicinal Natural Products, School of Pharmacy, West China University of Medical Sciences, Chengdu 610041 Chengdu Institute of Biology, Chinese Academy of Sciences, Cheng | 2000 | Chinese Chemical Letters2000，11，5： | 1 |
| 19 | Cell surviva;promoted by the Ras-MAPK signaling pathway by transcription dependent and independent mechanisms显示文摘 | Bo nni A Brunet A West A E | | 0，，5443： | 1 |
| 20 | Sol-gel processing of ceramics显示文摘 | Spiccia L Watkins ID West BO | 1996 | Materials Forum: Materials Processing1996，20，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员